Compare Stocks

Date Range: 

 Neptune Wellness SolutionsNovacytOpen OrphanKaleido BiosciencesSynairgen
SymbolTSE:NEPTLON:NCYTLON:ORPHNASDAQ:KLDOLON:SNG
Price Information
Current PriceC$1.60GBX 419.20GBX 37.75$7.46GBX 105.10
52 Week RangeBuyHoldN/ABuyN/A
MarketRank™
Overall Score1.20.60.01.50.4
Analysis Score3.50.00.03.30.0
Community Score2.51.90.02.02.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.01.70.0
Earnings & Valuation Score0.01.30.00.60.0
Analyst Ratings
Consensus RecommendationBuyHoldN/ABuyN/A
Consensus Price TargetC$4.63N/AGBX 19$17.90N/A
% Upside from Price Target189.06% upsideN/A-49.67% downside139.95% upsideN/A
Trade Information
Market CapC$264.79 million£296.06 million£252.70 million$317.19 million£210.11 million
BetaN/AN/AN/A0.02N/A
Average Volume577,748958,2673,185,983323,7282,303,126
Sales & Book Value
Annual RevenueC$52.78 million£78.23 million£10.57 millionN/A£79,000.00
Price / Sales5.023.7823.90N/A2,659.62
CashflowC$0.23 per shareGBX 30 per shareGBX 2.98 per shareN/AGBX 7.30 per share
Price / Cash6.8413.9712.65N/A14.40
Book ValueC$0.92 per shareGBX 89.40 per shareGBX 6 per shareN/AGBX 7.70 per share
Price / Book1.740.050.06N/A0.14
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($1.35)GBX 51.50GBX (3.20)($3.36)GBX (5.10)
Trailing P/E RatioN/A8.14N/AN/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.75%3.86%20.36%N/A1.80%
Current Ratio4.01%2.41%2.72%N/A6.20%
Quick Ratio2.69%1.79%2.57%N/A6.18%
Ownership Information
Institutional Ownership PercentageN/AN/AN/A79.91%N/A
Insider Ownership PercentageN/AN/AN/A10.00%N/A
Miscellaneous
Employees1651101328214
Shares Outstanding165.49 million70.63 million669.40 million42.52 million199.91 million
Next Earnings Date6/8/2021 (Estimated)N/A6/21/2021 (Estimated)8/3/2021 (Estimated)5/24/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Synairgen (LON:SNG) Share Price Crosses Above Fifty Day Moving Average of $155.12Synairgen (LON:SNG) Share Price Crosses Above Fifty Day Moving Average of $155.12
americanbankingnews.com - May 4 at 2:44 AM
Synairgens inhaled treatment lowers Covid-19 hospitalisation rate - Clinical Trials ArenaSynairgen's inhaled treatment lowers Covid-19 hospitalisation rate - Clinical Trials Arena
clinicaltrialsarena.com - May 3 at 8:30 AM
Synairgen Drops After Releasing Covid-19 Drug Trial Data (1) - Bloomberg LawSynairgen Drops After Releasing Covid-19 Drug Trial Data (1) - Bloomberg Law
news.bloomberglaw.com - April 30 at 1:10 PM
Proactive news headlines: Gfinity, Synairgen, Chaarat Gold, Destiny Pharma... - Proactive Investors UKProactive news headlines: Gfinity, Synairgen, Chaarat Gold, Destiny Pharma... - Proactive Investors UK
proactiveinvestors.co.uk - April 30 at 1:10 PM
Synairgen price target maintained at 505p by broker finnCap - Proactive Investors UKSynairgen price target maintained at 505p by broker finnCap - Proactive Investors UK
proactiveinvestors.co.uk - April 30 at 1:10 PM
Stocks that soared on COVID treatments are coming back to Earth - BNNStocks that soared on COVID treatments are coming back to Earth - BNN
bnnbloomberg.ca - April 30 at 8:09 AM
Small Cap Value Report (Fri 30 April 2021) - CARD | Paul Scott - StockopediaSmall Cap Value Report (Fri 30 April 2021) - CARD | Paul Scott - Stockopedia
stockopedia.com - April 30 at 3:08 AM
Stocks That Soared on Covid Treatments Are Coming Back to Earth - BloombergStocks That Soared on Covid Treatments Are Coming Back to Earth - Bloomberg
bloomberg.com - April 30 at 3:08 AM
Synairgen announces data from Home Cohort of SG016 Phase II - GlobeNewswireSynairgen announces data from Home Cohort of SG016 Phase II - GlobeNewswire
globenewswire.com - April 30 at 3:08 AM
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trialSynairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
finance.yahoo.com - April 30 at 3:08 AM
Braveheart Inv Share ChatBraveheart Inv Share Chat
lse.co.uk - April 24 at 4:34 AM
NIH trial to evaluate antibody therapeutic for Covid-19 treatment - Clinical Trials ArenaNIH trial to evaluate antibody therapeutic for Covid-19 treatment - Clinical Trials Arena
clinicaltrialsarena.com - April 22 at 10:29 AM
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19 - National Institutes of HealthLarge NIH clinical trial will test polyclonal antibody therapeutic for COVID-19 - National Institutes of Health
nih.gov - April 21 at 11:14 PM
Parexels Owner Is Said to Weigh Sale of Drug-Trial Company - BloombergParexel's Owner Is Said to Weigh Sale of Drug-Trial Company - Bloomberg
bloomberg.com - April 19 at 8:53 PM
Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $152.95Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $152.95
americanbankingnews.com - April 17 at 1:12 AM
Synairgen Shares Are Trading Almost Flat for the Year, but Could Breakout - AskTradersSynairgen Shares Are Trading Almost Flat for the Year, but Could Breakout - AskTraders
asktraders.com - April 12 at 9:09 AM
UK small-cap shares: 2 Covid-19-related stocks Id buy right now - Motley Fool UKUK small-cap shares: 2 Covid-19-related stocks I'd buy right now - Motley Fool UK
fool.co.uk - March 16 at 3:27 PM
The Synairgen share price is up 680% in a year! Should I buy now? - Motley Fool UKThe Synairgen share price is up 680% in a year! Should I buy now? - Motley Fool UK
fool.co.uk - March 12 at 8:55 AM
NIH to study three experimental COVID-19 treatments - MarketWatchNIH to study three experimental COVID-19 treatments - MarketWatch
marketwatch.com - March 4 at 7:01 PM
The Synairgen share price: here’s why I’d buy and hold this stockThe Synairgen share price: here’s why I’d buy and hold this stock
fool.co.uk - February 23 at 1:14 PM
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatientsSynairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
finance.yahoo.com - February 15 at 9:54 AM
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon betaSynairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
finance.yahoo.com - January 20 at 4:29 AM
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patientsSynairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
finance.yahoo.com - January 13 at 2:29 AM
COVID-19 Clinical Programme UpdateCOVID-19 Clinical Programme Update
finance.yahoo.com - December 18 at 7:53 AM
Companies Like Synairgen (LON:SNG) Are In A Position To Invest In GrowthCompanies Like Synairgen (LON:SNG) Are In A Position To Invest In Growth
finance.yahoo.com - December 14 at 8:55 AM
DateCompanyBrokerageAction
12/4/2020Neptune Wellness SolutionsAlliance Global PartnersLower Price Target
5/17/2020Neptune Wellness SolutionsCowenBoost Price Target
3/11/2021NovacytOddo BhfInitiated Coverage
3/11/2021NovacytOddo SecuritiesInitiated Coverage
7/28/2020Open OrphanFinnCapReiterated Rating
3/15/2021Kaleido BiosciencesMorgan StanleyLower Price Target
3/4/2021Kaleido BiosciencesCanaccord GenuityReiterated Rating
2/9/2021Kaleido BiosciencesPiper SandlerInitiated Coverage
1/14/2021Kaleido BiosciencesChardan CapitalBoost Price Target
12/23/2020Kaleido BiosciencesJMP SecuritiesInitiated Coverage
10/14/2020Kaleido BiosciencesJPMorgan Chase & Co.Initiated Coverage
3/25/2019Kaleido BiosciencesThe Goldman Sachs GroupInitiated Coverage
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.